Left atrial appendage closure - Current status and future directions

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Medical Device Technology

Background:

• Atrial fibrillation (AF) increases stroke risk, necessitating effective prevention strategies.
• Percutaneous left atrial appendage closure (LAAC) provides a non-pharmacological option for stroke risk reduction.
• LAAC is particularly crucial for patients with high bleeding risk who cannot tolerate anticoagulation.

Purpose of the Study:

• To review recent, current, and future studies on percutaneous left atrial appendage closure (LAAC).
• To analyze the safety and long-term efficacy of leading LAAC devices and their next-generation iterations.
• To explore the expanding role of LAAC in stroke prevention for non-valvular atrial fibrillation (AF) patients.

Main Methods:

• Comprehensive literature review of studies focusing on LAAC procedures.
• Analysis of data pertaining to the Watchman device and the Amplatzer cardiac plug (ACP).
• Examination of clinical evidence for next-generation devices: Watchman FLX and Amulet.

Main Results:

• Growing evidence supports the safety and long-term efficacy of LAAC in specific patient populations.
• Increased adoption of LAAC devices for stroke prevention in non-valvular AF.
• Ongoing research focuses on technological advancements and expanding the eligible patient pool for LAAC.

Conclusions:

• Percutaneous left atrial appendage closure is an established and evolving intervention for stroke prevention in AF.
• Continued research and device development are expanding the utility and accessibility of LAAC.
• LAAC offers a vital alternative for patients at high risk of bleeding on anticoagulation therapy.